Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19 - 26/11/20
, Sean P. Callahan a, Robert A. Brevetta a, Antine E. Stenbit a, Wesley M. Smith a, Julie C. Martin a, Anna V. Blenda b, Sergio Arce b, W. Jeffery Edenfield a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Objectives |
Cytokine release syndrome (CRS) is a potentially severe complication of COVID-19 most commonly resulting in respiratory failure. This ten-patient study was designed to determine the efficacy of therapeutic plasma exchange (TPE) in improving oxygenation and in reducing the cytokine load in a critically ill subset of patients.
Methods |
Five single volume plasma exchanges over eight days within a 14-day study period. In mechanically ventilated patients, oxygenation was measured via the PaO2/FiO2 (P/F) ratio and the oxygenation index (OI) daily for 14 days. Supplemental oxygen requirements were tracked daily for non-ventilated patients.
Results |
Non-ventilated patients were liberated from supplemental oxygen after TPE. The response was rapid with an 87% average reduction in oxygenation requirements following and average time to return to room air of 5.25 days. All mechanically ventilated patients demonstrated improvement in oxygenation with a 78% average improvement in the P/F ratio and a 43% improvement in OI. C-reactive protein (CRP) and serum levels of IL-6, IL-8, IL-10, TNFα, IFNγ and GM-CSF, were measured daily with immediate post TPE levels drawn on days 1, 2, 4, 6 and 8. All patients demonstrated significant reductions in CRP, IL-6, IL-10 and TNFα.
Conclusions |
In the majority of patients with Penn class 3 and 4 CRS complicating COVID-19, TPE demonstrated a prompt improvement in oxygenation and reduction in cytokine load without compromising patient safety. As this pilot study was envisioned to be hypothesis generating, expanded trials using TPE alone and in conjunction with novel pharmacologic agents are warranted.
Registration |
ClinicalTrials.gov NCT04374149.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Plasmapheresis can effectively reduce injurious cytokines that complicate COVID-19. |
• | Plasmapheresis can produce clinically meaningful improvement in oxygenation. |
• | Plasmapheresis can be safely used as a treatment for COVID-19 cytokine storm. |
Keywords : Therapeutic plasma exchange, COVID-19, Cytokine release syndrome, Respiratory failure, Oxygenation, Therapeutic benefit
Plan
Vol 175
Article 106188- décembre 2020 Retour au numéro
Article précédent
- RETRACTED: Targeting MALAT1 and miRNA-181a-5p for the intervention of acute lung injury/acute respiratory distress syndrome
- Yaling Liu, Xiaodong Wang, Peiying Li, Yanhua Zhao, Liqun Yang, Weifeng Yu, Hong Xie
- Risk factors for the development of post-infectious bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia in the era of increasing macrolide resistance
- Eun Lee, Yun Young Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.